Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

0 days.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Six-month results from the Phase 2 efficacy study demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in the study.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to www.medivation.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Liti
'"/>




Page: 1 2 3

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/6/2009)...Newswire-FirstCall/ -- Caraco Pharmaceutical Labor...rolac tromethamine ophthalmic solution, 0.5% follo...ministration (FDA) for Sun Pharma,s Abbreviated Ne... ophthalmic solution on the first day following pa...rapeutically equivalent to Acular® Ophthalmic...
(Date:11/6/2009)... America,s Specialty Med... of mid-market and smaller innovator pharmaceutica...962, the "Affordable Health Care for America Act,"...se smaller companies fear that the cumulative effe...r their efforts to bring new medicines to market. ...
(Date:11/6/2009)...ov. 6 Facet Solutions, Inc. announ...f Archus Orthopedics. The acquisition creates an u..., intellectual property and clinical experience in... patients suffering from lumbar spinal stenosis," ... Pardo. "This consolidation further strengthens F...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Facet Solutions Acquires Archus Orthopedics 2The Chinese Drywall Complaint Center Says There is No Independence Day for Homeowners in Florida Texas or Other States With Toxic Chinese Drywall 50236 1The Chinese Drywall Complaint Center Says There is No Independence Day for Homeowners in Florida Texas or Other States With Toxic Chinese Drywall 50236 2The Chinese Drywall Complaint Center Says There is No Independence Day for Homeowners in Florida Texas or Other States With Toxic Chinese Drywall 50236 3Paraplegic Takes Leap of Faith for Treatment in India 50232 1Paraplegic Takes Leap of Faith for Treatment in India 50232 2Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 1Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 2Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 3Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 4Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 5Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 6Data Demonstrates Long Term Reduction In Seizure Frequency With Novel Once Daily Anti Epileptic Zebinix 28R 29 4660 7
(Date:11/8/2009)...lth advocates committed to achieving meaningful he... "Tonight the U.S. Hous...ice of America,s families by passing the Affordabl... deliver, without delay, on the promise of meaning... President and CEO of the National Alliance for Hi...
(Date:11/8/2009)...Secure the Stability of Medicare ,, HOUSTON, N...table to: J. James Rohack, M.D., President, Americ...newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ,...eform bill, which will help improve the health sys...t passage of H.R. 3961 to secure the stability of ...
(Date:11/8/2009)...rking Families vs. Insurance Companies ,, HARR...the heels of an historic late night vote in the Ho... care reform bill, the Pennsylvania AFL-CIO releas...ives voted on HR 3962, the Affordable Health Care ...sed Saturday evening by a vote of 220 to 215, take...
(Date:11/7/2009).../ -- Karen Ignagni, President and CEO of America,s...wing statement today on House passage of H.R. 3962...ve health care reform, and we have contributed to ...f how health insurance is provided. Earlier this y...of pre-existing condition exclusions, no longer ba...
(Date:11/7/2009)...- The American Medical Association (AMA) proudly p...ily Violence Prevention Fund, with the Citation fo...olicy-making meeting. The Citation for Distinguis...Delegates bestows on a non-physician. ,, (Log.../AMALOGO ) ,, "Ms. James has worked selflessl...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
... likely to reduce the risk of contacting HIV from .... A recent study involved 3,000 HIV negative men i...cised and other half were not circumcised. They ...umcised men contracted the virus. Further researc...
...olled for early health check up programs and atten...be healthier adults than those who do not. A ...ildren who had participated early in these health ... Early Education Program that had community based ...
... by the ‘Delhi High Court’ on Tuesday Justice Vikr... Hospital to compensate Manju a 12 year old for th...the hospital. He wanted to be informed in the next...eplacement and fixation of fracture dislocation of...
...e to Listeria can be life-threatening unless vigi...ing to the report published by Food Safety Author...tion can be as much as 30% associated with Listeri...ociated with L. monocytogenes is uncertain, howeve...
...g from problem gambling behavior may share their p...drug addicts and alcoholics. Researchers have...em gambling behavior in people and have found mark...vior may not represent the entire gamut of people ...
... Bath in England an interesting study has been con.../ men. This is despite the popular notion that th...one as yet knows. “Until fairly recently it ... the case,” said Dr Ed Keogh a psychologist from t...
Other Medicine News:Health News:Listeria Food Poisoning Can Be Dangerous In Pregnant Women And Elderly 2Health News:Gender difference in Pain Experience - Women feel More Pain than men 2
...to provide fast and accurate measurements of patie...identification and quantitation of hemoglobin vari...control., ,The A1c assay combines the speed an...affinity columns. The result is a precise assessme...
Roche COMPACT 3 Blood Gas Analyzer
IRMA TRUPOINT Blood Analysis System
Flatbed Agitator PFS42
Medicine Products: